Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

56.55
-0.3050-0.54%
Volume:571.96K
Turnover:32.48M
Market Cap:5.33B
PE:-118.68
High:57.53
Open:57.21
Low:56.36
Close:56.85
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.42
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:217.36
PE(LYR):-197.47

Loading ...

Travere CMO Jula Inrig disposes of USD 345,520 Travere Therapeutics shares

Reuters
·
Apr 16

Travere Therapeutics Inc : JP Morgan Raises Target Price to $51 From $41

THOMSON REUTERS
·
Apr 15

BRIEF-Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 15

Travere Therapeutics grants inducement RSUs covering 17,420 shares to new hires

Reuters
·
Apr 15

Travere Therapeutics Up Over 34%, on Track for Highest Close Since May 2005 -- Data Talk

Dow Jones
·
Apr 15

Travere Therapeutics Inc : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $49 From $38

THOMSON REUTERS
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

Travere Therapeutics up 43% in premarket at $43.81 on FDA approval for Filspari

TIPRANKS
·
Apr 14

Ligand price target raised to $250 from $244 at BofA

TIPRANKS
·
Apr 14

Ligand Partner Travere Therapeutics Receives Full FDA Approval for Filspari® (Sparsentan) in Fsgs

THOMSON REUTERS
·
Apr 14

Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities

TIPRANKS
·
Apr 14

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
Apr 14

BRIEF-Travere Therapeutics Announces Full FDA Approval Of Filspari® (Sparsentan), The First And Only Approved Medicine For Fsgs

Reuters
·
Apr 14

Travere Therapeutics announces full FDA approval of FILSPARI

TIPRANKS
·
Apr 14

US FDA expands approval for Travere Therapeutics' drug for rare kidney disease

Reuters
·
Apr 14

Travere says FDA grants full approval to Filspari for FSGS proteinuria reduction

Reuters
·
Apr 14

Travere Therapeutics Announces Full FDA Approval of Filspari® (Sparsentan), the First and Only Approved Medicine for Fsgs

THOMSON REUTERS
·
Apr 14

Travere Therapeutics:Filspari Indicated to Reduce Proteinuria in Adults & Children Aged 8 Years & Older With Fsgs Who Do Not Have Nephrotic Syndrome

THOMSON REUTERS
·
Apr 14

Travere Therapeutics Inc - Filspari Indication Expands Addressable Population to Over 100,000 in U.S.

THOMSON REUTERS
·
Apr 14

Travere Therapeutics Inc - Filspari Available Only Through Filspari Rems Program

THOMSON REUTERS
·
Apr 14